Abstract:The group of AGC protein kinases includes more than 60 protein kinases in the human genome (e.g. PDK1 and isoforms of PKA, PKC, PRK, PKB/Akt, S6K, SGK, RSK, MSK, ROCK, GRK, amongst others). This group is also widely represented in other eukaryotes, including organisms that cause human infectious diseases. Human AGC kinases are involved in diverse cellular functions and are potential targets for the treatment of cancer, diabetes, obesity, neurological disorders, inflammation, viral infections, etc. Small molecule inhibitors of AGC kinases can also be considered as potential candidates for the development of targeted therapies against infectious diseases. AGC kinases are typically regulated by phosphorylation at three sites, the activation loop, the Zipper/turn-motif and the hydrophobic motif sites, and by other diverse mechanisms including intramolecular interactions with other regions of the protein, oligomerization, interaction with regulatory subunits, and second messengers. Interestingly, we were able to identify that a particular pocket on the kinase domain, termed the PIF-pocket, is a key mediator of the allosteric regulation of many AGC kinases. We first described the regulatory properties of the PIF-pocket on PDK1 [1]. Follow-up work verified that the PIF-pocket is also the key site that mediates the activation by Zipper/ turn-motif and hydrophobic motif phosphorylation of PKB/Akt, S6K, RSK, SGK, PKC, PRK, and MSK [2–4]. Interaction with the PIF-pocket also regulates the intramolecular inhibition of atypical PKCs by their N-terminal domains [5] and the oligomerization that inhibits PRK2 [6]. Moreover, we have developed reversible low-molecular-weight compounds that, by targeting the PIF-pocket site, allosterically activate PDK1 [7, 8], or allosterically inhibit atypical PKCs [5]. Our studies have shed light on the molecular details of the mechanism of allosteric regulation by small compounds and support the future development of drugs directed to the PIF-pocket of AGC kinases. The PIF-pocket regulatory site shares similar features with a dimerization regulatory site recently discovered on receptor tyrosine kinases, suggesting that the deep Invited Lectures

Small Molecules That Allosterically Inhibit P21-Activated Kinase Activity by Binding to the Regulatory P21-Binding Domain.

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase

P-21 Activated Kinases in Liver Disorders

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

Biology of the p21-Activated Kinases

Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation

L 2 The curious case of the inhibition of the p 90 ribosomal S 6 kinase by a plant flavonol glycoside , SL 0101

[Life-cycle assessment of single-use versus reusable surgical drapes (cellulose/polyethylene-mixed cotton system)].

Small Molecules Targeting Phosphoinositide 3-Kinases

Pyranonaphthoquinone Lactones: a New Class of AKT Selective Kinase Inhibitors Alkylate a Regulatory Loop Cysteine.

[P21-Activated Kinases and Their Role in the Nervous System].

Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities

Discovery of Novel Naphthoquinone Derivatives As Inhibitors of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase.

P21-activated Kinase 1 and Breast Cancer

Discovery of Lactoquinomycin and Related Pyranonaphthoquinones As Potent and Allosteric Inhibitors of AKT/PKB: Mechanistic Involvement of AKT Catalytic Activation Loop Cysteines

Redesign of the PAK1 Autoinhibitory Domain for Enhanced Stability and Affinity in Biosensor Applications

Hair Growth Promoting and Anticancer Effects of p21-activated kinase 1 (PAK1) Inhibitors Isolated from Different Parts of Alpinia zerumbet